January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Hung Trinh: Bispecific Antibodies in Cancer Therapy
Jan 20, 2025, 14:17

Hung Trinh: Bispecific Antibodies in Cancer Therapy

Hung Trinh, CMC/MFG Consultant and Managing Director at Vertex Biopharm Consulting, shared a post on LinkedIn about a recent paper by Mercedes Herrera et al. published in Trends in Cancer:

“A comprehensive review: Bispecific antibodies: advancing precision oncology

Bispecific antibodies (bsAbs) offer a novel approach to anticancer therapy by targeting different antigens via a range of mechanisms of action.

Manipulating bsAb structures allows generation of multiple formats to optimize molecular function for specific clinical contexts.

Thus far, a total of seven bsAbs have received regulatory approval for use in hematological malignancies and four in select solid tumors, with notable clinical efficacy.

The toxicities associated with the use of bsAbs need bespoke management strategies and expertise in clinical use. Understanding mechanisms of resistance to bsAbs is crucial to rational combination regimens or sequencing with other therapeutics to improve patient outcomes.

Bispecific antibodies (bsAbs) are engineered molecules designed to target two different epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets and structure (or format), which can be manipulated to create variable and novel functionalities, including linking immune cells with tumor cells, or dual signaling pathway blockade.

Several bsAbs have already changed the treatment landscape of hematological malignancies and select solid cancers. However, the mechanisms of resistance to these agents are understudied and the management of toxicities remains challenging.

Herein, we review the principles in bsAb engineering, current understanding of mechanisms of action and resistance, data for clinical application, and provide a perspective on ongoing challenges and future developments in this field.”

“Bispecific antibodies: advancing precision oncology”

Authors: Mercedes Herrera, Giulia Pretelli, Jayesh Desai, Elena Garralda, Lillian Siu, Thiago Steiner, Lewis Au.

Hung Trinh: Bispecific Antibodies in Cancer Therapy

More posts featuring Hung Trinh.